The synthesis and biological activity of novel glycoprotein IIb–IIIa anatagonists containing 3- azaspiro [5.5] undec-9-yl nucleus are described. The potent activity of these compounds as platelet aggregation inhibitors demonstrates the utility of the monoazaspirocyclic structure as central template for nonpeptide RGD mimics.